{"result": "\n{\n    \"title\": \"Drotrecogin Alfa Activated and PROWESS-SHOCK Study\",\n    \"summary\": \"The community centers around Drotrecogin Alfa Activated, a drug used in the treatment of severe sepsis, and the PROWESS-SHOCK study, which evaluated its efficacy. Key entities include Eli Lilly, the manufacturer and sponsor of the study, and various geographical regions where the study was conducted. The study's findings have significant implications for the treatment of severe sepsis and the regulatory landscape.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the potential implications of the study's findings on the treatment of severe sepsis and regulatory decisions.\",\n    \"findings\": [\n        {\n            \"summary\": \"Drotrecogin Alfa Activated's role in severe sepsis treatment\",\n            \"explanation\": \"Drotrecogin Alfa Activated, also known as recombinant human activated protein C, is a drug used in the treatment of severe sepsis. It is known for its antithrombotic, anti-inflammatory, and profibrinolytic properties. The drug was studied in a phase 3 trial to evaluate its effectiveness in reducing mortality among severe sepsis patients by decreasing inflammation and inhibiting thrombin generation [Data: Entities (275); Relationships (556, 777, 778, 779, 780)].\"\n        },\n        {\n            \"summary\": \"PROWESS-SHOCK study and its implications\",\n            \"explanation\": \"The PROWESS-SHOCK study was a clinical trial conducted to evaluate the efficacy of Drotrecogin Alfa Activated in reducing mortality in patients with septic shock. Despite initial support from the PROWESS study, the PROWESS-SHOCK study found that Drotrecogin Alfa Activated did not significantly reduce mortality in this patient population. This finding has important implications for the drug's use and regulatory approval [Data: Entities (2, 3); Relationships (1, 15, 17, 19, 27)].\"\n        },\n        {\n            \"summary\": \"Eli Lilly's involvement in the study\",\n            \"explanation\": \"Eli Lilly, a pharmaceutical company, played a significant role in the development and marketing of Drotrecogin Alfa Activated. The company funded the PROWESS-SHOCK study and was involved in its design and execution. Eli Lilly's involvement underscores the commercial and research interests tied to the drug's success and regulatory approval [Data: Entities (1); Relationships (0, 23, 24, 25, 26)].\"\n        },\n        {\n            \"summary\": \"Geographical scope of the clinical trial\",\n            \"explanation\": \"The clinical trial for Drotrecogin Alfa Activated was conducted across multiple regions, including Europe, North America, South America, and India. Europe was a major recruitment site, with 71.7% of study patients enrolled from this region. The geographical diversity of the trial sites highlights the global interest in the drug's potential benefits and the need for diverse patient populations in clinical research [Data: Entities (11, 12, 13, 23); Relationships (5, 6, 7, 10, 44, 45)].\"\n        },\n        {\n            \"summary\": \"Regulatory challenges and outcomes\",\n            \"explanation\": \"The regulatory landscape for Drotrecogin Alfa Activated has been complex. The European Medicines Agency granted marketing authorization for the drug, subject to annual review, while the FDA limited its approval to patients with a high risk of death and requested additional trials. These regulatory decisions reflect the challenges in balancing the drug's potential benefits against its efficacy and safety profile [Data: Entities (4, 5); Relationships (3, 4)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n291,ACTIVATED PROTEIN C,\"Activated protein C is a protein known for its anti-inflammatory properties and plays a significant role in the mechanism of action of drotrecogin alfa activated. It is also utilized as a treatment in clinical trials, which may influence the generalizability of the trial results.\",4\n275,DROTRECOGIN ALFA ACTIVATED,\"Drotrecogin Alfa Activated, also known as recombinant human activated protein C, is a drug used in the treatment of severe sepsis. It is known for its antithrombotic, antiinflammatory, and profibrinolytic properties. The treatment has been studied in a phase 3 trial, where it was used to reduce the rate of death from severe sepsis by decreasing inflammation and inhibiting thrombin generation. In this study, Drotrecogin Alfa Activated was compared against a placebo group to evaluate its effectiveness in reducing mortality among severe sepsis patients.\",15\n11,EUROPE,Europe is a continent where 71.7% of the study patients were recruited for the clinical trial. The study conducted in Europe was supported by the European Society of Intensive Care. It is one of the regions where patients were enrolled for the study.,9\n12,NORTH AMERICA,\"North America is a continent that served as one of the regions where patients were enrolled for the clinical trial, with 14.1% of the study patients being recruited from this area.\",4\n13,SOUTH AMERICA,\"South America is a continent that served as one of the regions where patients were enrolled for the clinical trial. Some of the study patients were recruited from this region, contributing to the overall research effort.\",4\n19,AUGUST 2011,AUGUST 2011 marks the month and year when patient enrollment concluded for the study. The study successfully completed its patient enrollment phase in August 2011.,3\n23,INDIA,\"India is a country where some of the study patients were recruited for the clinical trial. It is one of the countries where the study was conducted, with centers participating in the research.\",3\n18,MARCH 2008,MARCH 2008 marks the time when patient enrollment began for the study.,3\n25,\"MAY 12, 2010\",,2\n1,ELI LILLY,\"Eli Lilly is a pharmaceutical company that funded the PROWESS-SHOCK study and was involved in the development and marketing of DrotAA. Additionally, Eli Lilly is the sponsor of the study and the manufacturer of DrotAA (Xigris), a drug used in the study.\",8\n2,PROWESS-SHOCK,The PROWESS-SHOCK study is a clinical trial conducted to evaluate the efficacy of DrotAA in reducing mortality in patients with septic shock,3\n3,PROWESS,The Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study was a phase 3 international trial that initially supported the approval of DrotAA for severe sepsis,2\n27,ADDRESS TRIAL,The ADDRESS trial is a study that showed DrotAA did not reduce mortality in patients with severe sepsis who had a low risk of death,1\n4,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA for the treatment of adults with severe sepsis and multiple organ failure, subject to annual review\",1\n5,FOOD AND DRUG ADMINISTRATION,The FDA limited the approval of DrotAA for use in patients with a high risk of death and requested additional trials,1\n26,PROWESS STUDY,\"The PROWESS study is a previous trial that reported a reduction in mortality at 28 days with DrotAA, which was not replicated in the current study\",1\n28,RESOLVE TRIAL,The RESOLVE trial is a study that showed DrotAA did not reduce mortality in pediatric patients with severe sepsis,1\n288,PROTEIN C DEFICIENCY,\"Protein C Deficiency is a condition that was analyzed in the study, where it was observed in a significant number of patients. This deficiency affects their coagulation and influences the response to Drotrecogin Alfa Activated treatment.\",2\n16,INDEPENDENT DATA AND SAFETY MONITORING BOARD,\"The Independent Data and Safety Monitoring Board was responsible for conducting interim analyses during the CORTICUS study. This board met after each of the three interim analyses to ensure the safety and integrity of the data. Their role was to assess both the efficacy and safety of the study, thereby maintaining the study's overall reliability and ethical standards.\",3\n287,CENTRAL RANDOMIZATION CENTER,The central randomization center is responsible for assigning patients to treatment groups in the study,1\n289,D-DIMER,D-Dimer is a fibrin degradation product that is measured in studies to assess the effect of Drotrecogin Alfa Activated on thrombin generation. The levels of D-Dimer decrease with treatment using Drotrecogin Alfa Activated.,1\n276,VANDERBILT COORDINATING CENTER,\"The Vanderbilt Coordinating Center in Nashville served as the clinical coordinating center for the trial, providing 24-hour support for patient eligibility and safety inquiries\",1\n277,THROMBOMODULIN,\"Thrombomodulin is a protein that, when coupled with thrombin, converts protein C to activated protein C, playing a role in modulating coagulation and inflammation during sepsis\",1\n290,INTERLEUKIN-6,Interleukin-6 is a cytokine whose levels were measured in the study to evaluate the anti-inflammatory effects of Drotrecogin Alfa Activated.,1\n292,THROMBIN,\"Thrombin is an enzyme that plays a role in blood coagulation, whose generation is inhibited by drotrecogin alfa activated\",1\n293,NEUTROPHILS,\"Neutrophils are a type of white blood cell involved in inflammation, whose activation is inhibited by drotrecogin alfa activated\",1\n294,MAST CELLS,\"Mast cells are immune cells involved in allergic reactions and inflammation, whose degranulation is decreased by drotrecogin alfa activated\",1\n368,BRUSSELS,Brussels is the capital city of Belgium and is also the location where several hospitals and universities involved in the trial are situated.,2\n344,EUROPEAN SOCIETY OF INTENSIVE CARE,The European Society of Intensive Care is an organization that supported the study through the European Critical Care Research Network,2\n371,VALLADOLID,\"Valladolid is a city in Spain, known for being the location of the Rio Hortega University Hospital.\",2\n370,CHARLEROI,\"Charleroi is a city in Belgium, known for being the location of the Centre Hospitalier Universitaire de Charleroi.\",1\n15,DIAGNOSTICA STAGO,\"Diagnostica Stago is a company based in Asnieres, France, known for providing specialized diagnostic kits used in medical studies. The company supplies the Liatest D-D1 latex agglutination test kit, which is utilized for D-dimer level assays. Additionally, Diagnostica Stago provides the STA-Staclot protein C kit, both of which are integral to the research and studies in which they are employed.\",2\n369,VIENNA,Vienna is the city where the Medical University of Vienna is located,1\n20,CLINICAL COORDINATING CENTER,,1\n9,DUKE CLINICAL RESEARCH INSTITUTE,The Duke Clinical Research Institute performed the analysis for the study,1\n317,BELGIUM,Belgium is a country in Western Europe and is one of the countries where the multicenter trial was conducted.,3\n319,SPAIN,Spain is a country in Southwestern Europe. It is also one of the countries where the multicenter trial was conducted.,3\n295,CYTOKINES,\"Cytokines are signaling proteins that mediate and regulate immunity and inflammation, whose production is inhibited by activated protein C\",1\n296,E-SELECTIN,\"E-selectin is a cell adhesion molecule involved in the adhesion of cells to vascular endothelium, whose activity is inhibited by activated protein C\",1\n318,AUSTRIA,Austria is one of the countries where the multicenter trial was conducted,2\n8,NCT00604214,,1\n282,ASNIERES,Asnieres is the location in France where Diagnostica Stago is based,1\n345,EUROPEAN CRITICAL CARE RESEARCH NETWORK,A network that received support from the European Society of Intensive Care for the study,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n19,DROTAA,SEPTIC SHOCK,\"DrotAA was tested as a treatment for patients with septic shock. However, studies have shown that DrotAA is ineffective as a treatment for this condition.\",91\n172,SEPTIC SHOCK,ACTIVATED PROTEIN C,The use of activated protein C in the trial may have affected the results related to septic shock,74\n15,DROTAA,PLACEBO,\"DrotAA was compared to placebo in a study involving critically ill adults with septic shock, showing no significant difference in mortality\",52\n279,PLACEBO GROUP,DROTRECOGIN ALFA ACTIVATED,\"In a study aimed at evaluating the efficacy of Drotrecogin Alfa Activated in treating severe sepsis, Drotrecogin Alfa Activated was compared to a placebo group. The research focused on assessing the effects of Drotrecogin Alfa Activated in patients suffering from severe sepsis, providing insights into its potential benefits over a placebo.\",50\n46,EUROPE,PLACEBO,Europe was a major recruitment site for patients receiving placebo in the clinical trial,40\n53,NORTH AMERICA,PLACEBO,North America was a recruitment site for patients receiving placebo in the clinical trial,35\n54,SOUTH AMERICA,PLACEBO,South America was a recruitment site for patients receiving placebo in the clinical trial,35\n67,AUGUST 2011,PLACEBO,Patient enrollment for the placebo group ended in August 2011,34\n8,DROTAA,AUSTRALIA,Australia was a recruitment site for patients receiving DrotAA in the clinical trial,34\n89,INDIA,PLACEBO,India was a recruitment site for patients receiving placebo in the clinical trial,34\n66,MARCH 2008,PLACEBO,Patient enrollment for the placebo group began in March 2008,34\n91,PLACEBO,\"MAY 12, 2010\",\"The sample size for the placebo group was increased on May 12, 2010\",33\n9,DROTAA,NEW ZEALAND,New Zealand was a recruitment site for patients receiving DrotAA in the clinical trial,32\n14,DROTAA,APACHE II,APACHE II scores were used to assess the severity of illness in patients receiving DrotAA,32\n556,SEVERE SEPSIS,DROTRECOGIN ALFA ACTIVATED,\"Drotrecogin Alfa Activated is used as a treatment for severe sepsis. In studies and trials, it has been employed to treat patients with this condition, resulting in a reduction in the rate of death. The treatment has demonstrated a reduction in mortality and is noted to have an acceptable safety profile.\",32\n5,DROTAA,EUROPE,Europe was a major recruitment site for patients receiving DrotAA in the clinical trial,30\n0,DROTAA,ELI LILLY,\"Eli Lilly is the manufacturer of DrotAA, a drug that was used in the PROWESS-SHOCK study. Eli Lilly not only developed and marketed DrotAA but also funded the PROWESS-SHOCK study, demonstrating their significant involvement in both the research and commercial aspects of the drug.\",29\n6,DROTAA,NORTH AMERICA,North America was a recruitment site for patients receiving DrotAA in the clinical trial,25\n7,DROTAA,SOUTH AMERICA,South America was a recruitment site for patients receiving DrotAA in the clinical trial,25\n13,DROTAA,AUGUST 2011,Patient enrollment for the DrotAA group ended in August 2011,24\n1,DROTAA,PROWESS-SHOCK,The PROWESS-SHOCK study was conducted to test the efficacy of DrotAA in reducing mortality in septic shock patients,24\n10,DROTAA,INDIA,India was a recruitment site for patients receiving DrotAA in the clinical trial,24\n12,DROTAA,MARCH 2008,Patient enrollment for the DrotAA group began in March 2008,24\n20,DROTAA,CLINICIANS,\"Clinicians were previously using DrotAA to treat patients with septic shock, but the treatment is no longer available\",24\n2,DROTAA,PROWESS,The PROWESS study initially supported the approval of DrotAA for severe sepsis,23\n11,DROTAA,\"MAY 12, 2010\",\"The sample size for the DrotAA group was increased on May 12, 2010\",23\n27,ELI LILLY,DROTRECOGIN ALFA ACTIVATED,Eli Lilly developed drotrecogin alfa activated for the treatment of severe sepsis,23\n117,APACHE II SCORE,DROTRECOGIN ALFA ACTIVATED,Drotrecogin Alfa Activated treatment effects were analyzed in subgroups defined by the APACHE II Score,23\n17,DROTAA,ADDRESS TRIAL,\"The current study's findings are consistent with the ADDRESS trial, which showed DrotAA did not reduce mortality in patients with severe sepsis\",22\n3,DROTAA,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA, subject to annual review\",22\n4,DROTAA,FOOD AND DRUG ADMINISTRATION,The FDA limited the approval of DrotAA and requested additional trials,22\n16,DROTAA,PROWESS STUDY,\"The current study's findings contrast with the PROWESS study, which reported a reduction in mortality at 28 days with DrotAA\",22\n18,DROTAA,RESOLVE TRIAL,\"The current study's findings are consistent with the RESOLVE trial, which showed DrotAA did not reduce mortality in pediatric patients with severe sepsis\",22\n777,DROTRECOGIN ALFA ACTIVATED,ACTIVATED PROTEIN C,Drotrecogin alfa activated exerts its effects through the antiinflammatory and antithrombotic properties of activated protein C,19\n558,SEVERE SEPSIS,PROTEIN C DEFICIENCY,Protein C deficiency is a condition that affects patients with severe sepsis in the study,19\n56,INDEPENDENT DATA AND SAFETY MONITORING BOARD,DROTRECOGIN ALFA ACTIVATED,The independent data and safety monitoring board conducted interim analyses to assess the efficacy of drotrecogin alfa activated,18\n774,DROTRECOGIN ALFA ACTIVATED,PROTEIN C DEFICIENCY,Drotrecogin Alfa Activated showed consistent effects in patients with and without Protein C Deficiency,17\n773,DROTRECOGIN ALFA ACTIVATED,CENTRAL RANDOMIZATION CENTER,The central randomization center assigned patients to receive drotrecogin alfa activated or placebo,16\n775,DROTRECOGIN ALFA ACTIVATED,D-DIMER,\"Drotrecogin Alfa Activated is a therapeutic agent known for its ability to reduce plasma D-Dimer levels. This reduction in D-Dimer levels indicates a decrease in thrombin generation, showcasing the biologic activity of Drotrecogin Alfa Activated. By decreasing D-Dimer levels, Drotrecogin Alfa Activated effectively demonstrates its role in modulating coagulation processes.\",16\n771,DROTRECOGIN ALFA ACTIVATED,VANDERBILT COORDINATING CENTER,The Vanderbilt Coordinating Center provided support for the trial involving drotrecogin alfa activated,16\n772,DROTRECOGIN ALFA ACTIVATED,THROMBOMODULIN,\"Thrombomodulin is involved in the conversion process that activates protein C, which is the basis for drotrecogin alfa activated\",16\n776,DROTRECOGIN ALFA ACTIVATED,INTERLEUKIN-6,\"Drotrecogin Alfa Activated is known for its anti-inflammatory activity, as evidenced by its ability to decrease Interleukin-6 levels. This reduction in Interleukin-6, a pro-inflammatory cytokine, highlights the therapeutic potential of Drotrecogin Alfa Activated in managing inflammatory responses.\",16\n778,DROTRECOGIN ALFA ACTIVATED,THROMBIN,\"Drotrecogin alfa activated inhibits the generation of thrombin, contributing to its antiinflammatory effects\",16\n779,DROTRECOGIN ALFA ACTIVATED,NEUTROPHILS,\"Drotrecogin alfa activated inhibits the activation of neutrophils, contributing to its antiinflammatory effects\",16\n780,DROTRECOGIN ALFA ACTIVATED,MAST CELLS,\"Drotrecogin alfa activated decreases the degranulation of mast cells, contributing to its antiinflammatory effects\",16\n26,ELI LILLY,STEERING COMMITTEE,The steering committee designed the study in collaboration with Eli Lilly,16\n57,INDEPENDENT DATA AND SAFETY MONITORING BOARD,CORTICUS STUDY,The board monitored data safety and integrity during the CORTICUS study,15\n44,EUROPE,NORTH AMERICA,Patients were enrolled from both Europe and North America for the study,13\n45,EUROPE,SOUTH AMERICA,Patients were enrolled from both Europe and South America for the study,13\n90,INDIA,HIGH-FREQUENCY OSCILLATORY VENTILATION (HFOV),India was one of the countries where the HFOV study was conducted,13\n30,PROWESS,APACHE II,The APACHE II score was used in the PROWESS study to identify patients with increased illness severity,13\n48,EUROPE,BRUSSELS,Brussels is a city located in Europe,11\n22,ELI LILLY,NEJM,The full text of the study sponsored by Eli Lilly is available on NEJM.org,11\n25,ELI LILLY,INDEPENDENT DATA AND SAFETY MONITORING BOARD,The independent data and safety monitoring board conducted interim analyses for the study sponsored by Eli Lilly,11\n47,EUROPE,EUROPEAN SOCIETY OF INTENSIVE CARE,The European Society of Intensive Care is based in Europe and supported the study,11\n51,EUROPE,VALLADOLID,Valladolid is a city located in Europe,11\n50,EUROPE,CHARLEROI,Charleroi is a city located in Europe,10\n24,ELI LILLY,DIAGNOSTICA STAGO,Diagnostica Stago provided the STA-Staclot protein C kit for the study sponsored by Eli Lilly,10\n49,EUROPE,VIENNA,Vienna is a city located in Europe,10\n23,ELI LILLY,CLINICAL COORDINATING CENTER,The clinical coordinating center worked on the study sponsored by Eli Lilly,9\n21,ELI LILLY,DUKE CLINICAL RESEARCH INSTITUTE,The Duke Clinical Research Institute performed the analysis for the study sponsored by Eli Lilly,9\n52,NORTH AMERICA,SOUTH AMERICA,Patients were enrolled from both North America and South America for the study,8\n65,MARCH 2008,AUGUST 2011,The study enrolled patients from March 2008 to August 2011,6\n796,BELGIUM,SPAIN,Both Belgium and Spain were locations where the multicenter trial was conducted,6\n29,PROWESS-SHOCK,INSTITUTIONAL REVIEW BOARD,The Institutional Review Board approved the PROWESS-SHOCK study at each study center,6\n784,ACTIVATED PROTEIN C,CYTOKINES,Activated protein C inhibits the production of cytokines by lipopolysaccharide-challenged monocytes,5\n785,ACTIVATED PROTEIN C,E-SELECTIN,Activated protein C inhibits E-selectin–mediated adhesion of cells to vascular endothelium,5\n798,AUSTRIA,SPAIN,Both Austria and Spain were locations where the multicenter trial was conducted,5\n795,BELGIUM,AUSTRIA,Both Belgium and Austria were locations where the multicenter trial was conducted,5\n797,BELGIUM,BRUSSELS,Brussels is the capital city of Belgium,5\n799,SPAIN,VALLADOLID,Valladolid is a city in Spain,5\n28,PROWESS-SHOCK,NCT00604214,NCT00604214 is the ClinicalTrials.gov number associated with the PROWESS-SHOCK study,4\n55,DIAGNOSTICA STAGO,ASNIERES,\"Diagnostica Stago is based in Asnieres, France\",3\n837,EUROPEAN SOCIETY OF INTENSIVE CARE,EUROPEAN CRITICAL CARE RESEARCH NETWORK,The European Society of Intensive Care supported the study through the European Critical Care Research Network,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}